Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non-Current Liabilities (2022 - 2025)

Taysha Gene Therapies' Other Non-Current Liabilities history spans 4 years, with the latest figure at $1.4 million for Q2 2025.

  • For Q2 2025, Other Non-Current Liabilities fell 96.44% year-over-year to $1.4 million; the TTM value through Jun 2025 reached $1.4 million, down 96.44%, while the annual FY2024 figure was $1.3 million, 16.99% down from the prior year.
  • Other Non-Current Liabilities for Q2 2025 was $1.4 million at Taysha Gene Therapies, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $42.1 million in Q1 2024 and bottomed at $1.2 million in Q1 2025.
  • The 4-year median for Other Non-Current Liabilities is $3.8 million (2023), against an average of $8.7 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 952.17% in 2024 before it crashed 97.15% in 2025.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $4.1 million in 2022, then tumbled by 61.82% to $1.6 million in 2023, then dropped by 16.99% to $1.3 million in 2024, then rose by 6.65% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Other Non-Current Liabilities are $1.4 million (Q2 2025), $1.2 million (Q1 2025), and $1.3 million (Q4 2024).